



AUTOSOMAL DOMINANT CEREBELLAR ATAXIA INCLUDING SCA 2, SCA 3, SCA 7 AND SCA 12 : AN OVERVIEW

Genetics

Barkha Singh	Department of Anatomy, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005, Uttar Pradesh, India
Prasenjit Bose	Department of Anatomy, All India Institute of Medical Sciences, Raipur, 492099, Chhattisgarh, India.
S N Shamal	Department of Anatomy, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005, Uttar Pradesh, India
Deepika Joshi	Department of Neurology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005, Uttar Pradesh, India
Royana Singh*	Department of Anatomy, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005, Uttar Pradesh, India *Corresponding Author

KEYWORDS

INTRODUCTION

Spinocerebellar ataxias (SCAs) are a heterogeneous group of neurodegenerative disorders. The CAG repeat expansions in the causative genes are the principal cause of SCAs and these have been used for the classifications and diagnoses of patients with ataxia. Spinocerebellar ataxia (SCA), previously known as autosomal dominant cerebellar ataxia, is a biologically strong group of relatively 30 progressive neurodegenerative diseases. The more prevalent Spinocerebellar ataxias like SCA1, SCA2, SCA3, and SCA6 along with SCA7 and SCA17 are brought about by CAG repeat expansion, that encodes a polyglutamine tract in the affected protein¹. Present day studies advocate that the mutated protein results in pathogenesis within the context of its "normal" cellular function. Hence, decoding the cellular function of these proteins might help in the development of therapeutics.

Ataxia primarily occurs because of degeneration of neurons in the brain stem, cerebellum, spinocerebellar tracts, and their afferent/efferent connections. As many as 50 different types of inherited ataxias are there that strike during childhood or adulthood (Taroni and DiDonato, 2004; Manto, 2005).

Classification

Autosomal dominant cerebellar ataxias (ADCA) are classified into three categories by Harding in 1981, Type I, Type II and Type III. ADCA Type I includes syndromes such as SCA1- SCA4, SCA8, SCA10, SCA12 - SCA23, SCA25, SCA27, SCA28 and DRPLA. ADCA Type II consists of syndromes associated with pigmentary maculopathies and comprises SCA7. ADCA Type III consists of pure cerebellar syndromes and includes SCA5, SCA6, SCA11, SCA26, SCA29, SCA30 and SCA31². ADCA Type I phenotypes are complex and comprises ataxia and other neurological signs. The clinical spectrum is very wide and it ranges from just "pure" cerebellar signs to constellations including peripheral nerve disease, spinal cord syndromes, cognitive impairment, cerebellar or supranuclear ophthalmologic signs, seizure disorders and psychiatric problems³. Type I ADCA pathogenesis is not fully understood. Based on proposed pathogenesis, categories of Type I ADCA have been recommended. Thus, there are 3 major subclasses. The first and supposedly most common subclass includes SCA1, SCA2, SCA3, and SCA17; and DRPLA that are associated with expansions of trinucleotide CAG repeat, encoding large nonstop and continuous glutamine tracts. The second important pathogenic subclass comprises those ADCA Type I such as SCA8, SCA10 and SCA12, where expansions of trinucleotide repeat fall outside of the protein coding region of the disease gene. The last sub-class includes SCA13, SCA14, SCA15/16, SCA27 and SCA28 caused by missense mutations, nonsense mutations and specific gene deletions, resulting in neurodegeneration⁴.

Our work is basically upon Autosomal dominant spinocerebellar ataxia 2, 3, 7 and spino cerebellar ataxia 12.

Spinocerebellar ataxia 2 (SCA 2)

Spinocerebellar ataxia 2 (SCA 2) belongs to the family of autosomal dominant cerebellar ataxias (ADCA) a genetically heterogenous group of neurodegenerative diseases. Spinocerebellar ataxia type 2 (SCA2) is a disorder indicated by progressive problems with movement. SCA2 occurs because of mutation in the ATXN2 gene known as a trinucleotide repeat expansion. The length of the repeated CAG segment in the ATXN2 gene is increased because of this mutation. If CAG repeats in the ATXN2 are 32 or more, then SCA2 might occur in the subjects. SCA 2 had located the locus for SCA2 that mapped to chromosome 12q24^{5,6}.

Spinocerebellar ataxia 3 (SCA 3)

Spinocerebellar Ataxia Type 3 (SCA3), commonly known as **Machado-Joseph Disease (MJD)** is a polyglutamine neurodegenerative disorder which occurs because of expansion of a (CAG)_n in the ATXN3 gene. 11 to 44 CAG repeats are considered normal, whereas pathogenic extensions range from 61 to 87 CAGs⁷. Cerebellar ataxia, ocular rotatory muscles palsy, gaze-evoked nystagmus, pyramidal and extrapyramidal signs, as well as sleep disorders are the characteristic features seen in SCA3. The age of onset of SCA3/MJD is not fixed, but most commonly occurs in the second to fifth decade. This disease is the most common form of autosomal dominant ataxia, globally and several studies related to this disorder, have been reported⁸. ATXN3 gene located on chromosome 14q32.1^{9,10}.

Spinocerebellar Ataxia type 7 (SCA 7)

Spinocerebellar ataxia 7 (SCA7) is one of the type, a group of inherited neurodegenerative disorders including spinal and bulbar muscular atrophy/Kennedy's disease, Huntington's disease, spinocerebellar ataxia types 1, 2, 3, 6, 7 and 17, and dentato-rubro-pallidolusian atrophy^{11,12}. This disorder commonly presents with cerebellar ataxia and progressive retinal degeneration and are also related with neuronal loss of Purkinje cells in the cerebellum and loss of cone-photoreceptor cells in the retina are peculiar symptoms of SCA7. The polyQ tract sequence is located at the N-terminal region of ATXN7 protein. Normally 4–35 cytosine-adenine-guanine repeats are noticed in ATXN7, however 36–306 repeats are seen in pathogenic variants¹³. The gene responsible for the SCA7 phenotype is found to be located at chromosome 3p12-21.1^{14,15}. In addition mapping of this region allowed the researchers to test the hypothesis, that a CAG repeat expansion was involved¹⁶. Initial studies of the ataxin-7 CAG repeat proved that expansions beyond 37 CAG's resulted in SCA7 disease phenotype, and normal persons retains ataxin-7 repeats ranging in size from 7 to 34 CAG's¹⁷. There is also an interrelationship between repeat length and the type of clinical presentation in SCA7 disorder, with repeat mutations

of < 59 CAGs often shows cerebellar findings first and those > 59 CAGs generally producing visual impairment as the earliest symptom¹⁸. Before gene discovery, on the basis of presence of retinopathy, at the beginning SCA7 was differentiated from the chief category of autosomal dominant cerebellar ataxia (ADCA) as ADCA type II¹⁹. At present, unstable CAG repeat expansion in the coding zone of the ataxin-7 gene is the only recognized gene defect responsible for ADCA type II²⁰. The very common clinical feature and often the first reported symptom of SCA7 is cerebellar ataxia, which is established as troubled walking, speech and manual dexterity²¹. In the due course of time, more comprehensive neurological deficits like dysphagia, dysarthria, hypoacusis and eye movement abnormalities (slow saccades; staring) that can progress to frank ophthalmoplegia, develop in SCA7 patients. Exaggerated deep tendon reflexes, extensor plantar reflexes and spasticity could be present due to the involvement of the cortico-spinal tracts²². A pattern of genetic anticipation is noticed in SCA7 families where successive generations establish more severe forms of the disease after inheriting longer repeat expansions than were present in their clan and this occurs because the causative gene in SCA7 is an unstable CAG repeat. SCA7 might present as an early onset rapidly progressive juvenile type or even a very serious infantile type, if very long repeats are inherited. Because of its extensive disease pathology, infantile-onset SCA7 is significant and this includes organ systems outside the central nervous system (CNS). On doing Magnetic Resonance Imaging (MRI) of SCA7 patients, marked atrophy of the cerebellum and pons is typically noticed, although few patients may also exhibit high T2 signal intensity in transverse pontine fibers. Researches have proved that volume loss may occur in the pons before the development of cerebellar atrophy and this suggests that the initial site of disease onset could be in brainstem structures rather than in the cerebellar folia²³. In SCA7 patients, cerebellar tissue shows considerable loss of cerebellar PCs although only mild changes are observed in the cerebellar granule cell layer. In the inferior olive, there is noticeable neuronal loss with gliosis. Demyelination of the posterior columns of the spinal cord and of the pyramidal tracts may also takes place²⁴. The presence of nuclear inclusions is one of the pathological features of SCA7.

Spinocerebellar ataxia 12 / PPP2R2B

SCA 12 disease is also known as PPP2R2B, which occurs because of a CAG repeat expansion in a promoter region of PPP2R2B located on chromosome 5q32. The most characteristic feature of this disease is action tremor. SCA12 is frequently seen in Caucasians, while few cases have been reported among Indians and Chinese. The disease exhibits inter/intra familial phenotypic heterogeneity. Brain imaging usually reveals both cerebral and cerebellar atrophy with relative sparing of brainstem, thalamus, basal ganglia and other subcortical brain regions²⁵.

Epidemiology

Autosomal Dominant Cerebellar ataxias are of more than 30 different forms, associated with mutations in over 20 genes, have been described, with a global prevalence of 1:35,000 individuals. SCA2 is more prevalent in Cuba, India, Mexico, and Southern Italy.

To establish the prevalence and distribution of MJD/SCA3 in the Cuba, a clinical and molecular genetic study of a cohort of SCA3 families was developed. SCA3 was not validated in the replication cohorts, probably due to the low prevalence of intermediate alleles at this locus. This was already illustrated in a homogeneous SCA3 Brazilian cohort²⁶. The prevalence of SCA3 is 0.26 cases/100 000 and a frequency of 4.1% among the dominant ataxias in Cuba.

SCA7 is mainly a rare disease, with an incidence of less than 1/100,000. The prevalence is of about 6 per 100,000²⁷. Although the various genetic subtypes of ADCA are mainly found in various populations worldwide, their frequencies differs because its depending on the population studies.

The prevalence of SCA 12 is unknown. On the other hand, in India, SCA12 is mainly limited to one endogamic population; however, 5–8% of families with SCA12 have been reported from other ethnic communities²⁸.

DISCUSSION

In this review, we characterize the clinical, molecular, genetic and phenotypic aspects of ADCA. Till date a lot of research has taken place which provides a better platform to understand the genetic and

molecular mechanisms related to ADCA. Nonetheless, the Harding classification is still significant, and this is very useful in detecting the type of autosomal dominant cerebellar ataxia. At present, there are no adequate treatments to modify disease progression.

REFERENCES

1. Cell biology of spinocerebellar ataxia, Harry T. Orr, J Cell Biol. 2012. Apr 16; 197(2): 167–177.
2. Harding AE. The clinical features and classification of the late onset autosomal dominant cerebellar ataxias. A study of 11 families, including descendants of the 'the Drew family of Walworth'. Brain. 1982;105(Pt 1):1–28.
3. Whaley N, Uitti R. In: Neurology and Clinical Neuroscience. Schapira A, editor. Philadelphia: Mosby Inc; 2007. Inherited ataxias; pp. 887–897.
4. Soong BW, Paulson HL. Spinocerebellar ataxias: an update. Current Opinion in Neurology. 2007;20(4):438–446. doi: 10.1097/WCO.0b013e3181fbd3dd.
5. Gispert S, Twells R, et al. Chromosomal assignment of the second locus for autosomal dominant cerebellar ataxia (SCA2) to chromosome 12q23-24.1. Nature Genetics. 1993;4(3):295–299. doi: 10.1038/ng0793-295.
6. Nechiporuk A, Lopes-Cendes L, et al. Genetic mapping of the spinocerebellar ataxia type 2 gene on human chromosome 12. Neurology. 1996;46(6):1731–1735.
7. Whaley NR, Fujioka S, et al. Autosomal dominant cerebellar ataxia type I: a review of the phenotypic and genotypic characteristics. Orphanet J Rare Dis. 2011;28:6–33.
8. Durr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol. 2010;9:885–94.
9. Lima L, and Coutinho, P. (1980) Clinical criteria for diagnosis of Machado-Joseph disease: report of a non-Azorena Portuguese family. Neurology, 30, 319-322.
10. D'Abreu, A, Franca, et al (2010). Caring for Machado-Joseph disease: current understanding and how to help patients. Parkinsonism Relat. Disord., 16, 2-7.
11. Taylor J.P, Hardy J, et al. Toxic proteins in neurodegenerative disease. Science. 2002;296:1991–1995.
12. Garden G.A, La Spada A.R. Molecular pathogenesis and cellular pathology of spinocerebellar ataxia type 7 neurodegeneration. Cerebellum. 2008;7:138–149.
13. Benomar A, Krols L, et al. The gene for autosomal dominant cerebellar ataxia with pigmentary macular dystrophy maps to chromosome 3p12-p21.1. Nat Genet. 1995;10:84–8.
14. Holmberg M, Johansson J, et al. Localization of autosomal dominant cerebellar ataxia associated with retinal degeneration and anticipation to chromosome 3p12-p21.1. Hum Mol Genet. 1995;4:1441–5.
15. Trotter Y, Lutz Y, et al. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature. 1995;378:403–6.
16. David G, Abbas N, et al. Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet. 1997;17:65–70.
17. Johansson J, Forsgren L, et al. Expanded CAG repeats in Swedish spinocerebellar ataxia type 7 (SCA7) patients: effect of CAG repeat length on the clinical manifestation. Hum Mol Genet. 1998;7:171–6.
18. Harding AE. Classification of the hereditary ataxias and paraplegias. Lancet. 1983;1:1151–5.
19. David G, Abbas N, et al. Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet. 1997;17:65–70.
20. Giunti P, Stevanin G, et al. Molecular and clinical study of 18 families with ADCA type II: evidence for genetic heterogeneity and de novo mutation. Am J Hum Genet. 1999;64:1594–603.
21. David G, Durr A, et al. Molecular and clinical correlations in autosomal dominant cerebellar ataxia with progressive macular dystrophy (SCA7) Hum Mol Genet. 1998;7:165–70.
22. Bang OY, Lee PH, et al. Pontine atrophy precedes cerebellar degeneration in spinocerebellar ataxia 7: MRI-based volumetric analysis. J Neurol Neurosurg Psychiatry. 2004;75:1452–6.
23. Michalik A, Martin JJ, et al. Spinocerebellar ataxia type 7 associated with pigmentary retinal dystrophy. Eur J Hum Genet. 2004;12:2–15.
24. Martin J, Van Regemorter N, et al. Spinocerebellar ataxia type 7 (SCA7) - correlations between phenotype and genotype in one large Belgian family. J Neurol Sci. 1999;168:37–46.
25. Holmes WF, Soprano DR, et al. Early events in the induction of apoptosis in ovarian carcinoma cells by CD437: activation of the p38 MAP kinase signal pathway. Oncogene. 2003 Sep 25;22(41):6377–86.
26. Schols L, Bauer P, et al. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol. 2004;3:291–304.
27. J. Ataxias with autosomal, X-chromosomal or maternal inheritance. Can J Neurol Sci. 2009;36:409–28.
28. Ahal K, Srivastava, Mohammed Faruq, et al. Clinical behaviour of spinocerebellar ataxia type 12 and intermediate length abnormal CAG repeats in PPP2R2B. Journal of Neurology BRAIN 2017; 140: 27–36.